К вопросу о трансплантации печени у больных гепатоцеллюлярной карциномой (краткий обзор литературы)

Автор: Новрузбеков Мурад Сафтарович, Олисов Олег Даниелович

Журнал: Злокачественные опухоли @malignanttumors

Статья в выпуске: 4S1 (21), 2016 года.

Бесплатный доступ

Гепатоцеллюлярная карцинома (ГЦК) - одна из наиболее распространенных опухолей, занимающая лидирующие позиции в структуре летальности от онкологического заболевания. Первичный рак печени устойчиво ассоциируется с наличием хронического диффузного заболевания печени - вирусного гепатита и цирроза. Ортотопическая трансплантация печени -альтернативный и, возможно - оптимальный метод лечения ГЦК, так как в результате операции полностью удаляется пораженный орган и предраковое заболевание. Отдаленные результаты ОТП зависят от стадии опухолевого поражения, инвазии опухоли в сосуды печени. Золотым стандартом в определении показаний к ОТП при ГЦК принято считать «Миланские критерии» и «Барселонскую» классификацию, обеспечивающие прекрасные отдаленные результаты. Вместе с тем, многими авторами данные критерии признаются излишне строгими, необоснованно лишающими значительную часть больных перспективы трансплантации печени.

Еще

Гепатоцеллюлярная карцинома, трансплантация печени, "миланские" критерии, расширенные критерии

Короткий адрес: https://readera.ru/140223006

IDR: 140223006   |   DOI: 10.18027/2224-5057-2016-4s1-36-39

Список литературы К вопросу о трансплантации печени у больных гепатоцеллюлярной карциномой (краткий обзор литературы)

  • Khan A.S, et al. Current surgical treatment strategies for hepatocellular carcinoma in North America.//World J Gastroenterol 2014; 20(41): 15007-15017.
  • Bruix J., Sherman M. Management of Hepatocellular Carcinoma: An update (AASLD practice guideline)//Hepatology. July 2010.
  • Byam J, et al. Liver transplantation for hepatocellular carcinoma.//Hepatobiliary Surg Nutr 2013;2(1):22-30.
  • Elshamy M, et al. Hepatocellular carcinoma beyond Milan criteria: Management and transplant selection criteria//World J Hepatol 2016 July 28; 8(21): 874-880.
  • Mazzaferro V., et al. Liver transplantation for hepatocellular carcinoma.//Annals of Surgical Oncology 15(4):1001-1007.
  • Weledji E., et al. How grim is hepatocellular carcinoma?//Annals of Medicine and Surgery 3 (2014) 71-76.
  • Hackl C., et al. Liver transplantation for malignancy: current treatment strategies and future perspectives.//World J Gastroenterol 2014 May 14; 20(18): 5331-5344.
  • Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome.//ISRN Hepatology, Vol. 2014 (2014), Article ID706945, 25 pages.
  • Mazzaferro V, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.//N Engl J Med 1996; 334:693-699.
  • Clavien et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report.//Lancet Oncol. 2012 Jan; 13(1): e11-e22.
  • Mehta N, et al. Outcomes after Liver Transplantation for patients with hepatocellular carcinoma and a low risk of dropout from the transplant waiting list.//Liver Transpl. 2014; 20(5): 627-628.
  • Graziadei IW, et al. Chemoembolization followed by Liver Transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.//Liver Transpl 9(6):557-63, Jun 2003.
  • Llovet JM, et al. Prognosis of hepatocellular carcinoma: the BCLC staging classification.//Semin Liver Dis. 1999;19:329-338.
  • Yao FY, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.//Hepatology 2001; 33: 1394-1403.
  • Herrero JI, et al. Influence of tumor characteristics on the outcome of Liver Transplantation among patients with liver cirrhosis and hepatocellular carcinoma.//Liver Transpl 2001; 7: 631-636.
  • Roayaie S, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters.//Ann Surg 2002; 235: 533-539.
  • Kneteman NM, et al. Sirolimus-based immunosuppression for Liver Transplantation in the presence of extended criteria for hepatocellular carcinoma.//Liver Transpl 2004; 10: 1301-131.
  • Onaca N, et al. Expanded criteria for Liver Transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation.//Liver Transpl 2007; 13: 391-399.
  • Soejima Y, et al. Extended indication for living donor liver Transplantation in patients with hepatocellular carcinoma.//Transplantation 2007; 83: 893-899.
  • Jonas S, et al. Living donor Liver Transplantation of the right lobe for hepatocellular carcinoma in cirrhosis in a European center.//Liver Transpl 2007; 13: 896-903.
  • Sugawara Y, et al. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series.//Dig Dis 2007; 25: 310-312.
  • Silva M, et al. Expanded criteria for Liver Transplantation in patients with cirrhosis and hepatocellular carcinoma.//Liver Transpl 2008; 14: 1449-1460.
  • Mazzaferro V, et al; Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.//Lancet Oncol. 2009; 10: 35-43.
  • Kwon CH, et al. HCC in living donor liver transplantation: can we expand the Milan criteria?//Dig Dis 2007; 25: 313-319.
  • Takada Y, et al. Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria.//Dig Dis 2007; 25: 299-302.
  • Zheng SS, et al. Liver Transplantation for hepatocellular carcinoma: Hangzhou experiences.//Transplantation 2008; 85: 1726-1732.
  • Fujiki M, et al. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma.//Am J Transplant 2009; 9: 23622371.
  • Lai Q, et al. Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation.//Clin Transplant 2012; 26: E125-E131.
  • Grqt M, et al. Combination of morphologic criteria and a-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.//World J Surg 2014; 38: 2698-2707.
  • Toso C, et al. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation.//Hepatology 2015; 62: 158-165.
  • Lee SD, et al. Clinical impact of 18F-Fluorodeoxyglucose positron emission tomography/computed tomography in living donor liver Transplantation for advanced hepatocellular carcinoma.//Transplantation 2015; 99: 2142-2149.
  • See C. C., Sheung T. F. Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation.//Hepatobiliary Surg Nutr 2013;2(2):84-88.
  • Duffy J. P., et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.//Ann Surg 2007;246: 502-511.
  • Xu D. W., et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review.//World J Gastroenterol 2016; 22(12): 3325-3334.
  • Mazzaferro V., et al. Liver transplantation for hepatocellular carcinoma.//Annals of Surgical Oncology 15(4):1001-1007.
  • Chapman WC, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation.//Ann Surg 2008; 248: 617-625.
  • Yao FY, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis.//Hepatology 2008; 48: 819-827.
  • Vagefi PA, Hirose R. Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant Sorafenib in locoregional therapy?//J Gastrointest Canc (2010) 41:217-220.
  • Yoo EJ, et al. Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. OncoTargets and Therapy 2013:6 755759.
  • Bhardwaj N., et al. Current treatment approaches to HCC with a special consideration to transplantation.//Journal of Transplantation Volume 2016, Article ID7926264, 9 pages.
Еще
Статья научная